Wanted: Division of Biophysics, Biomedical Technology, and Computational Biosciences Director

BBCB Search Committee Members: Enrique De La Cruz, Yale University Daniel Gallahan, National Cancer Institute Jill Heemskerk, National Institute of Biomedical Imaging and Bioengineering Ming Lei, National Institute of General Medical Sciences, Chair Cathy Wu, University of Delaware The search is now open for an outstanding candidate to serve as director of our Division of Biophysics, Biomedical Technology, and Computational Biosciences (BBCB). The division supports the development of biophysical and computational methods and tools for understanding basic biological questions; physical and theoretical methodologies, data science and bioinformatics tools, and cutting-edge quantitative and computational approaches to better understand biological systems and lay the foundation for advances in disease diagnosis, treatment, and prevention; and the creation of innovative tools and new technologies for the study of macromolecular, cellular, and organelle processes and function. The division also administers NIGMS’ Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) program. This position offers a unique and exciting opportunity to set scientific priorities, lead change, and improve the biomedical research enterprise. The director of BBCB is a key member of the senior leadership team of the Institute and supervises a staff of approximately 11 program officers. Candidates must possess a Ph.D., M.D., or equivalent degree in a field...
Source: NIGMS Feedback Loop Blog - National Institute of General Medical Sciences - Category: Biomedical Science Authors: Tags: Job Announcements Source Type: blogs

Related Links:

Publication date: Available online 3 June 2020Source: Life SciencesAuthor(s): Milad Ashrafizadeh, Ali Zarrabi, Kiavash Hushmandi, Vahideh Zarrin, Ebrahim Rahmani Moghadam, Amirhossein Zabolian, Shima Tavakol, Saeed Samarghandian, Masoud Najafi
Source: Life Sciences - Category: Biology Source Type: research
Publication date: 1 September 2020Source: Life Sciences, Volume 256Author(s): Neda Khalili, Masoud Nouri-Vaskeh, Zahra Hasanpour Segherlou, Amir Baghbanzadeh, Monireh Halimi, Haleh Rezaee, Behzad Baradaran
Source: Life Sciences - Category: Biology Source Type: research
Publication date: Available online 2 June 2020Source: Colloids and Surfaces B: BiointerfacesAuthor(s): Ping Huang, Guanchun Wang, Zhaohong Wang, Cancan Zhang, Fengmian Wang, Xiaoxiao Cui, Sini Guo, Wei Huang, Rong Zhang, Deyue Yan
Source: Colloids and Surfaces B: Biointerfaces - Category: Biochemistry Source Type: research
Publication date: 24 September 2020Source: Inorganica Chimica Acta, Volume 510Author(s): Thankaraj Salammal Sheena, Rajakumaran Dhivya, Venkatesan Rajiu, K. Jeganathan, Mallayan Palaniandavar, Ganesan Mathan, Mohammad Abdulkader Akbarsha
Source: Inorganica Chimica Acta - Category: Chemistry Source Type: research
CONCLUSIONS: The introduction of spacer sequence between chelator and BBN(7-14) led to improved bidistribution. Analogue with tri-Gly spacer is the more promising radiopeptide for targeting GRP receptor than Ser conjugate. Therefore, these analogs can be considered as a candidate for the identification of bombesin-positive tumors. PMID: 32497000 [PubMed - as supplied by publisher]
Source: Current Radiopharmaceuticals - Category: Radiology Tags: Curr Radiopharm Source Type: research
Authors: Ao H, Li Y, Li H, Wang Y, Han M, Guo Y, Shi R, Yue F, Wang X Abstract Hydroxy genkwanin (HGK), a flavonoid compound from natural resources, showed good inhibition against the growth of breast tumor cells. However, the poor solubility restricted the further study and the in vivo drug delivery of HGK. We prepared HGK nanosuspensions by antisolvent precipitation method and investigated their characterization, stability, hemolysis probability, release behavior in vitro, antitumor activity in vitro and in vivo, and preliminary safety through acute toxicity experiments. The resultant HGK nano...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Authors: Zhang X, Ren X, Tang J, Wang J, Zhang X, He P, Yao C, Bian W, Sun L Abstract Multidrug resistance (MDR) of cancer cells is a significant challenge in chemotherapy, highlighting the urgent medical need for simple and reproducible strategies to reverse this process. Here, we report the development of an active tumor-targeting and redox-responsive nanoplatform (PA-ss-NP) using hyaluronic acid-g-cystamine dihydrochloride-poly-ε-(benzyloxycarbonyl)-L-lysine (HA-ss-PLLZ) to co-deliver paclitaxel (PTX) and apatinib (APA) for effective reversal of MDR. This smart nanoplatform specifically bound to CD44 rec...
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
Authors: Mookerjee S, Foster HR, Waller AK, Ghevaert CJ Abstract Platelet transfusions are given to patients in hospital who have a low blood platelet count (thrombocytopenia) either because of major bleeding (following trauma or surgery) or because the bone marrow production of platelets is impaired often due to chemotherapy, infiltration with malignant cells, fibrosis or genetic disorders. We are currently entirely reliant on blood donors as a source of platelets in transfusion medicine. However, the demand for platelets continues to rise, driven by an aging population, advances in medical procedures and ever mor...
Source: Platelets - Category: Hematology Tags: Platelets Source Type: research
I was a premed many years ago. I got a masters in molecular biology, was accepted to a school and then found out I was pregnant. This predates MomMd. I was given a year off, but I stupidly did not go back. I taugh bio at a university and took more courses. I had the chance to apply again and was in full-time MCAT study mode. Then I was diagnosed with cancer. Two years later, I was better. I felt med school was over. I had wanted to be a psychiatrist so badly. I decided to get a PhD in... I don’t like my job and don’t know what to do
Source: Student Doctor Network - Category: Universities & Medical Training Authors: Tags: Psychology [Psy.D. / Ph.D.] Source Type: forums
Purpose of review There are several first-line systemic therapy options for patients with newly diagnosed stage IV non-small-cell lung cancer. Targeted therapy with tyrosine kinase inhibitors provide a good first option for some. Unfortunately, most patients do not have an alteration for which there is an available tyrosine kinase inhibitor. For these patients there are immunotherapy and chemoimmunotherapy options; however, there is debate about how to choose amongst these treatments for a given individual. This review attempts to simplify this decision-making process. Recent findings The data on first-line immunother...
Source: Current Opinion in Pulmonary Medicine - Category: Respiratory Medicine Tags: NEOPLASMS OF THE LUNG: Edited by Alan M. Fein and David E. Ost Source Type: research
More News: Biomedical Science | Blogging | Cancer | Cancer & Oncology | Science | Small Businesses | Study | Yale